Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC).

David Gill(Intermountain Healthcare), Archana M. Agarwal(University of Utah), Emma Carroll(University of Utah), Austin Poole(University of Utah), Kenneth M. Boucher(University of Utah), Eric O. Johnson(RTI International), Andrew W. Hahn(The University of Texas MD Anderson Cancer Center), Neeraj Agarwal(University of Utah), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center)
Journal of Clinical Oncology
February 20, 2017
Cited by 4


Related Papers